Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 2009 Jun;157(4):551–553. doi: 10.1111/j.1476-5381.2009.00204.x

Vascular KATP channels: dephosphorylation and deactivation

Paolo Tammaro 1
PMCID: PMC2707967  PMID: 19630834

Abstract

Vascular ATP-sensitive potassium (KATP) channels (Kir6.1/SUR2B) are regulated by both cell metabolism and chemical transmitters. They are the target for a number of vasodilators and vasoconstrictors whose mechanisms of action involve activation of protein kinase A (PKA) and protein kinase C (PKC), respectively. The article by Orie et al. in this issue of the BJP sheds new light on the (opposing) role of protein phosphatases in the regulation of this ion channel activity. Their data suggest that calcineurin, a Ca2+-dependent protein phosphatase, modulates Kir6.1/SUR2B by inhibiting PKA-dependent phosphorylation of the channel. This novel mechanism may provide a modulation opposing the action of vasodilators on the KATP channel.

British Journal of Pharmacology (2009) 157, 551–553; doi:10.1111/j.1476-5381.2009.00204.x

This article is a commentary on Orie et al., pp. 554–564 of this issue and is part of a themed section on Endothelium in Pharmacology. For a list of all articles in this section see the end of this paper, or visit: http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2009

Keywords: Kir6.1, SUR2B, ATP-sensitive potassium channel, protein kinase A, calcineurin


ATP-sensitive potassium (KATP) channels serve as metabolic sensors that convert changes in cell metabolism into changes in electrical activity. In vascular smooth muscle (VSM), they contribute to the resting membrane potential and regulate the vessel tone. Alterations in their activity in response to vasoactive agonists, exercise or hypoxia cause changes in arterial diameter that play an important role in blood pressure regulation (Quayle et al., 1997). At present, little information is available on the contribution of endothelial KATP channels in vascular function. However, there is evidence that adenosine- and α2-adrenoceptor mediated vasodilation (Kuo and Chancellor, 1995; Gendron et al., 2004) may be dependent on endothelial KATP channels and a role for these channels in the regulation of coronary blood flow by modulation of the release of endothelin-1 has been proposed (Malester et al., 2007). The pivotal role of KATP channels in the vascular system is emphasized by the observation that genetic deletion (knockout) of either of its two subunits, SUR2 (Chutkow et al., 2002) or Kir6.1 (Miki et al., 2002), causes coronary vasospasm in mice.

KATP channels are an octameric complex of four sulphonylurea receptor subunits (SUR) surrounding a central pore composed of four inwardly rectifying subunits (Kir6.1 or Kir6.2). The hallmark of KATP channels is their sensitivity to inhibition by intracellular ATP. Additionally, Mg-nucleotides open KATP channels via interaction with SUR. Thus, reciprocal changes in the intracellular concentrations of ATP and MgADP underlie the metabolic regulation of KATP channels.

A property of VSM KATP channels is that they are targets for vasoactive hormones. For example, they are inhibited by angiotensin II (via protein kinase C (PKC) activation) and opened by cyclic-AMP-elevating vasodilators such as calcitonin gene-related peptide, adenosine, prostacyclin and vasoactive intestinal peptide through a mechanism which requires protein kinase A (PKA) activation (Quayle et al., 1997). PKA was shown to phosphorylate serine and threonine residues on both SUR2B and Kir6.1 (Quinn et al., 2004; Shi et al., 2008). Although the mechanisms of modulation of channel activity by PKA (and PKC) phosphorylation are well described, substantially less information is available on the opposing effects of protein phosphatases.

Previous studies have shown that calcineurin, a Ca2+-dependent protein phosphatase, can modulate KATP channel activity in isolated VSM cells (Wilson et al., 2000). Channel activity was inhibited as the intracellular Ca2+ concentration ([Ca2+]i) was increased within the nanomolar range. Furthermore, inhibition of calcineurin activity was proposed to underlie cases of a life-threatening syndrome (‘potassium-channel syndrome’) associated with excessive KATP channel activation in response to drugs (Singer et al., 2005). However, neither the site of action nor the calcineurin isoform involved in these effects were established.

Calcineurin is a Ca2+/calmodulin Ser/Thr phosphatase, consisting of a catalytic subunit (CnA), which interacts with calmodulin, and a regulatory subunit (CnB) bearing a Ca2+ binding site. Three isoforms of CnA (CnAα CnAβ, CnAγ) with high sequence homology but different tissue and cellular distribution, have been identified.

In this issue of the British Journal of Pharmacology, Orie and colleagues use an heterologous expression system (transfected HEK-293 cells) to explore the molecular mechanism of calcineurin modulation of KATP channels (Orie et al., 2009). Two possible mechanisms of action for calcineurin were considered: (i) direct channel dephosphorylation and (ii) a possible indirect effect via inhibition of PKA, since the type-2 regulatory (RII) subunit of PKA is a substrate for calcineurin.

The authors employed a combined pharmacological and biochemical approach in their study. By using chemically unrelated inhibitors of either PKA or calcineurin, they demonstrated the involvement of both these enzymes in regulating KATP channel function. Specifically, calcineurin inhibitors enhanced KATP current whereas blockers of PKA activity reduced resting KATP currents and the responses to calcineurin inhibitors. The latter observations are in accord with the hypothesis that calcineurin exerts its effects, at least in part, indirectly via PKA inhibition.

Activation of calcineurin, obtained by increasing [Ca2+]i (up to 36 nmol·L−1) in the pipette solution, however, abolished the stimulatory effect of a constitutively active form of PKA, which lacks the RII and is therefore insensitive to calcineurin inhibition. This supports the notion that calcineurin acts directly on the channel and that PKA and calcineurin can compete for the same phosphorylation site on the channel. Furthermore, in vitro phosphorylation assays provided direct evidence that the catalytic subunit, CnAα, can dephosphorylate a serine residue in Kir6.1, previously phosphorylated by PKA.

Two other additional important observations were made: (i) CnAα, but not CnAβ, modulates Kir6.1/SUR2B; (ii) surprisingly, neither PP1, a protein phosphatase that is activated by calcineurin, nor PKC are involved in this modulation.

In conclusion, the authors show that calcineurin is likely to be the major player in the Ca2+-dependent inhibition of Kir6.1/SUR2B and that this phosphatase suppresses channel activity by antagonising PKA-dependent phosphorylation.

The findings of this paper raise a number of important questions and no doubt will stimulate further research into how KATP channel activity is regulated by protein phosphatases. For instance, it will be important to determine if calcineurin can dephosphorylate those residues on SUR2B that have been found to be important for channel activation (Quinn et al., 2004; Shi et al., 2007).

The elucidation of the precise physiological significance for this novel regulatory mechanism will require further studies. A working model is that an increase of [Ca2+]i during agonist stimulation at G-protein coupled receptors would result in calcineurin activation and KATP channel inhibition. In native cells, this effect may occur in combination with the well-described inhibitory effect of PKC on KATP channel activity. It needs to be clarified whether these effects coexist in native VSM cells, which one is predominant and whether their contribution differs in the various vascular beds. Answering these questions is likely to require the use of knockouts or siRNA directed against CnAα or various PKC isoforms in combination with patch-clamp experiments on permeabilized native cells.

Kir6.1/SUR2B channels are also present in the endothelium. It remains to be seen if calcineurin modulates KATP channels in this cell type and what is the potential physiological consequence of this modulation.

Perhaps the most important clinical question arising from this work is whether calcineurin plays a role in those pathological conditions associated with Ca2+ mishandling, such as sepsis or pulmonary hypoxia, and whether KATP channels are regulated by calcineurin under those conditions.

Finally, It is noteworthy that calcineurin is an important modulator of other VSM channels, including, but not limited to, calcium-activated chloride-channels and voltage-gated Ca2+ channels. We do not know which of these targets for calcineurin contribute most to the global electrical activity of the cell and whether their contributions vary in the various vascular beds. Elucidation of this will provide exciting research opportunities for the future.

Themed Section: Endothelium in Pharmacology

Endothelium in pharmacology: 30 years on: J. C. McGrath

Role of nitroso radicals as drug targets in circulatory shock: E. Esposito & S. Cuzzocrea

Endothelial Ca2+-activated K+ channels in normal and impaired EDHF–dilator responses – relevance to cardiovascular pathologies and drug discovery: I. Grgic, B. P. Kaistha, J. Hoyer & R. Köhler

Endothelium-dependent contractions and endothelial dysfunction in human hypertension: D. Versari, E. Daghini, A. Virdis, L. Ghiadoni & S. Taddei

Nitroxyl anion – the universal signalling partner of endogenously produced nitric oxide?: W. Martin

A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries: K. L. Andrews, J. C. Irvine, M. Tare, J. Apostolopoulos, J. L. Favaloro, C. R. Triggle & B. K. Kemp-Harper

Vascular KATP channels: dephosphorylation and deactivation: P. Tammaro

Ca2+/calcineurin regulation of cloned vascular KATP channels: crosstalk with the protein kinase A pathway: N. N. Orie, A. M. Thomas, B. A. Perrino, A. Tinker & L. H. Clapp

Understanding organic nitrates – a vein hope?: M. R. Miller & R. M. Wadsworth

Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia: C. R. de Andrade, P. F. Leite, A. C. Montezano, D. A. Casolari, A. Yogi, R. C. Tostes, R. Haddad, M. N. Eberlin, F. R. M. Laurindo, H. P. de Souza, F. M. A. Corrêa & A. M. de Oliveira

Mechanisms of U46619-induced contraction of rat pulmonary arteries in the presence and absence of the endothelium: C. McKenzie, A. MacDonald & A. M. Shaw

This issue is available online at http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2009

Acknowledgments

P.T. holds a Research Council UK fellowship.

References

  1. Chutkow WA, Pu J, Wheeler MT, Wada T, Makielski JC, Burant CF, et al. Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels. J Clin Invest. 2002;110:203–208. doi: 10.1172/JCI15672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gendron ME, Thorin E, Perrault LP. Loss of endothelial KATP channel-dependent, NO-mediated dilation of endocardial resistance coronary arteries in pigs with left ventricular hypertrophy. Br J Pharmacol. 2004;143:285–291. doi: 10.1038/sj.bjp.0705937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kuo L, Chancellor JD. Adenosine potentiates flow-induced dilation of coronary arterioles by activating KATP channels in endothelium. Am J Physiol. 1995;269:H541–549. doi: 10.1152/ajpheart.1995.269.2.H541. [DOI] [PubMed] [Google Scholar]
  4. Malester B, Tong X, Ghiu I, Kontogeorgis A, Gutstein DE, Xu J, et al. Transgenic expression of a dominant negative KATP channel subunit in the mouse endothelium: effects on coronary flow and endothelin-1 secretion. Faseb J. 2007;21:2162–2172. doi: 10.1096/fj.06-7821com. [DOI] [PubMed] [Google Scholar]
  5. Miki T, Suzuki M, Shibasaki T, Uemura H, Sato T, Yamaguchi K, et al. Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat Med. 2002;8:466–472. doi: 10.1038/nm0502-466. [DOI] [PubMed] [Google Scholar]
  6. Orie NN, Thomas AM, Perrino BA, Tinker A, Clapp LH. Ca2+/calcineurin regulation of cloned vascular KATP channels: crosstalk with the protein kinase A pathway. Br J Pharmacol. 2009;157:554–564. doi: 10.1111/j.1476-5381.2009.00221.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev. 1997;77:1165–1232. doi: 10.1152/physrev.1997.77.4.1165. [DOI] [PubMed] [Google Scholar]
  8. Quinn KV, Giblin JP, Tinker A. Multisite phosphorylation mechanism for protein kinase A activation of the smooth muscle ATP-sensitive K+ channel. Circ Res. 2004;94:1359–1366. doi: 10.1161/01.RES.0000128513.34817.c4. [DOI] [PubMed] [Google Scholar]
  9. Shi Y, Wu Z, Cui N, Shi W, Yang Y, Zhang X, et al. PKA phosphorylation of SUR2B subunit underscores vascular KATP channel activation by beta-adrenergic receptors. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1205–1214. doi: 10.1152/ajpregu.00337.2007.. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Shi Y, Chen X, Wu Z, Shi W, Yang Y, Cui N, et al. cAMP-dependent protein kinase phosphorylation produces interdomain movement in SUR2B leading to activation of the vascular KATP channel. J Biol Chem. 2008;283:7523–7530. doi: 10.1074/jbc.M709941200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. Lancet. 2005;365:1873–1875. doi: 10.1016/S0140-6736(05)66619-6. [DOI] [PubMed] [Google Scholar]
  12. Wilson AJ, Jabr RI, Clapp LH. Calcium modulation of vascular smooth muscle ATP-sensitive K+ channels: role of protein phosphatase-2B. Circ Res. 2000;87:1019–1025. doi: 10.1161/01.res.87.11.1019. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES